In pancreatic cancer, active targeting appears to be essential, as we demonstrate superior survival of SDC1-Lip carrying echinomycin compared to echinomycin alone (S2VP10 p = 0.0096 and S2CP9 p = 0.0073) (Figure 6). Here, SDC1 is linked to pancreatic neoplasm.